Advanced Chronic Liver Disease Screening by Transient Elstography in Patients Hospitalised in a Psychiatric Unit
- Conditions
- Liver FibrosisPsychiatric DisorderPsychiatric HospitalizationAdvanced Chronic Liver Disease
- Interventions
- Diagnostic Test: non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)
- Registration Number
- NCT05602870
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders.
There are still many barriers to screening and linkage to care for patients having somatic illness.
Moreover follow-up of these patients may be difficult because of poor access to care, sometimes marginalization, and insufficient compliance with health programs.
The aim of this study is to asses acceptability of of advanced chronic liver disease screening by transient elstography (Fibroscan ®) in patients hospitalised in a psychiatric unit.
- Detailed Description
Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders.
There are still many barriers to screening and linkage to care for patients having somatic illness.
Moreover follow-up of these patients may be difficult because of poor access to care, sometimes marginalization, and insufficient compliance with health programs.
Transient elastography is a useful tool validated for early diagnosis advanced chronic liver disease.It is non-invasive, fast, and gives immediate results.
The aim of this study is to assess acceptability of of advanced chronic liver disease screening by transient elstography (Fibroscan ®) in patients hospitalised in psychiatric unit.
Moreover, we will estimate de prevalence of advanced chronic liver diseases according to specific causes in psychiatry unit We hypothesize that the fact of offering psichiatric patents a non-invasive analysis of hepatic fibrosis will improve the detection of serious liver diseases and linkage to care.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 180
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Psychiatric patient non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®) All patients having psychiatric disorders and hospitalised in a Psychiatry Unit of CHU Montpellier will have an non invasive evaluation of liver fibrosis after giving their consent
- Primary Outcome Measures
Name Time Method acceptability of non invasive assessement of liver fibrosis by Fibroscan in psychiatric patients At Inclusion Number of patient who have agreed to do fibroscan screening among patient to whom it was offered.
- Secondary Outcome Measures
Name Time Method Prevalence of advanced liver disease in psychiatric patients At inclusion Number of patient who are diagnosed with advanced liver disease among patient to whom it was offered.
prevalence of excessive alcohol or drug consumption in psychiatric patients At inclusion Number of patient with excessive alcohol/drug consumption
correlation between advanced chronic liver diseases and risk factors for liver diseases in psychiatric patients 1 to 3 month after inclusion Number of patients with advanced chronic liver disease among those having risk factors for chronic liver disease
assessment of referral to medical care when advanced fibrosis was diagnosed, regardless of its etiology 1 to 3 month after inclusion Number of patients that have actually came to their medical appoint after advanced fibrosis diagnosis
prevalence of passed or active drug consumption (intraveinous, inhaled or sniffed) in psychiatric patients At Inclusion Number of patient with excessive alcohol/drug consumption
prevalence of viral hepatitis in psychiatric patients At Inclusion Number of patient diagnosed with viral hepatitis B, D, C
reason for refusal of non invasive evaluation of chronic liver disease At Inclusion rate of reasons of refusal according to reason of hospitalization, sector, duration of hospitalization, time spend in study explaination, patient reflection time
Trial Locations
- Locations (1)
Montpellier University Hospital
🇫🇷Montpellier, France